|
- Regeneron | Pushing the Bounds of Science
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines Join our team and explore clinical trials
- Regeneron Pharmaceuticals - Wikipedia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc is an American biotechnology company headquartered in Westchester County, New York The company was founded in 1988 [2]
- PUSH THE BOUNDS OF SCIENCE - Regeneron
Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases
- Regeneron makes $150M bet on Tesseras rare disease gene writing . . .
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a prospect for alpha-1 antitrypsin deficiency (AATD) through $150
- Regeneron inks gene editing deal with startup Tessera
Regeneron Pharmaceuticals is putting more money into gene editing, announcing Monday a partnership with Tessera Therapeutics to develop an experimental program for a rare liver and lung disease At the center of the deal is a treatment Tessera, a well-funded startup backed by Flagship Pioneering, is developing for alpha-1 antitrypsin deficiency Regeneron is paying Tessera $150 million upfront
- About Regeneron | Our Company
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies
- Regeneron Makes $275M Gene Editing Play With Tessera Partnership . . .
Regeneron has forged a global collaboration with Tessera Therapeutics, looking to advance an in vivo gene editor for alpha-1 antitrypsin deficiency The partnership, announced Monday, will involve a $150 million upfront cash payment and equity investment from the pharma, as well as up to $125 million in near- and mid-term development milestones
- Regeneron and Tessera partner on gene editing therapy for rare disease
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Tessera Therapeutics Inc announced a collaboration to develop TSRA-196, an investigational gene editing therapy for alpha-1 antitrypsin
|
|
|